®copyright rubinfeld 2013 cxlusa clinical trial results s. lance forstot, md, facs corneal...

41
®Copyright Rubinfeld 20 Copyright Rubinfeld 20 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor of Ophthalmology University of Colorado School of Medicine

Upload: george-waters

Post on 25-Dec-2015

216 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CXLUSA Clinical Trial Results

S. Lance Forstot, MD, FACSCorneal Consultants of Colorado

Founding Partner

Clinical Professor of Ophthalmology

University of Colorado

School of Medicine

Page 2: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CXLUSA Clinical Trial Results

Roy S. Rubinfeld, MA, MD Georgetown University Medical Center,

Washington Hospital Center, Washington, DC

Dr. Rubinfeld has intellectual property Dr. Rubinfeld has intellectual property in corneal strengthening technology and in corneal strengthening technology and

financial interests in CXLO and CXLUSA financial interests in CXLO and CXLUSA

Page 3: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

o Non-commercial, physician-sponsored UV research studies approved by IRBs since

2009. No IP, no investors Limited number of centers

o Commercial start up with IP, investors, BOD, Novel Technology, Commercial Drug, Advisors

What’s What?

Page 4: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CXLUSA Study Group Centers

Page 5: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CXLUSA Study Group Centers

Page 6: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CXLUSA Study Group Centers

Page 7: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CXLUSA Study Group Centers

Page 8: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CXL Mythology

Page 9: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

Epi-Off is Better Epi-On is Better

Epithelium removal is needed to load the stroma

with riboflavin

See pictures

Page 10: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

Transepithelial Riboflavin Loading @12 min

Page 11: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

15 Min Epi-On CXLO (~20 y/o pt)Cobalt Blue Light SL Pix

Page 12: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Epi-on Flare

Page 13: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

Epi-Off is Better Epi-On is Better

With Epi-On CXL, the riboflavin only loads epithelium

which blocks the UVA and limits CXL

See picture

Page 14: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

15 Min Epi-On CXLO White Light SL Pix (18 y/o Pt)

Page 15: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

Epi-Off is Better Epi-On is Better

Epithelium off CXL is safer than epi-on

See pictures

Page 16: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Haze after Epi-Off CXL

Page 17: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Delayed Epithelial Healing and Infiltrate after Epi-Off CXL

Postop Day 2Postop Day 2

Courtesy of W. Trattler, MD Courtesy of W. Trattler, MD

Page 18: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013Postop Day 5Postop Day 5

Page 19: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

Perforation after Epi-Off CXL

Page 20: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Epi-off Complications

o Microbial keratitis after corneal collagen crosslinking. Perez-Santonja JCRS 2009;35(6):1138-40o Pseudomonas keratitis after collagen crosslinking for

keratoconus: case report and review of literature. Sharma. JCRS 2010;36(3):517-20o Complication and failure rates after corneal crosslinking.

Koller, Seiler, et. al. JCRS 2010;36(1):185o Permanent corneal haze after riboflavin-UVA-induced

cross-linking in keratoconus. Raiskup, Spoerl,  JRS2009 Sep;25(9):S824-8.

o Corneal melting in both eyes after simultaneous corneal cross-linking in a patient with keratoconus and Down syndrome. Ophthalmologe. 2010 Oct; 107(10):951-5

o Corneal melting corneal collagen cross-linking for keratoconus: A case report. Labiris. Journal of Medical Case Reports 5:15 2012

o Early ocular surface-related complications after CXL. Gutman. Modern Medicine Sept, 2012.

Page 21: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

Critical Balance of 3 Reactants is Essential

Riboflavin

UV light Oxygen

Page 22: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Clear Cornea- Epi-On CXL POD 1

Page 23: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Safety Treat thinner, steeper, younger corneas, Return to preop vision, function POD 1 Return to CLs in days 1 day of discomfort KCN as indication for PKP

Epi-On Advantages

Page 24: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Epi-on is not “better” if it doesn’t work

But

Page 25: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

Clinical Experience - Keratoconus

c/o William Trattler, MD

Vision Improvement (>= 1 line of vision) CXLUSA vs. Hersh/Avedro

N = 177 N = 48 N = 49 N = 48N = 177 N = 49

Page 26: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

1 Year Results (Advanced KCN)

Formulation 1 (36 eyes)

UCVA:Improved ≥1 Lines: 56%Worsened: 3%

No Change: 40%BSCVA:

Improved 1 ≥ Lines: 41%Worsened: 32%No Change: 24%

K Max: Avg Flattening vs. Pre Op=

1.55D

Formulation 2

(31 eyes)UCVA:

Improved ≥1 Lines: 64%Worsened: 8%No Change: 28%

BSCVA:Improved 1≥ Lines: 56%Worsened: 8%No Change: 35%

K Max:Avg Flattening vs. Pre Op=

1.41D

Page 27: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Epi- On CXLUSA Results

Page 28: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Stops ProgressionMild improvement in ~50% Can we do better

for advanced cases?

Limitations of CXL Alone

Page 29: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Terrific for early KCN before vision is lost CXL stops progression of vision loss and

corneal steepening For those who have lost vision from KCN

or ectasia, CXL usually yields only mild improvement in vision and topo/tomos

Can we do better for more adv cases?

Limitations of CXL Alone

Page 30: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

What if we Could Do This Consistently With Two Non-invasive Procedures?

Page 31: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

No Finger Pressure

Finger Pressure at

6 o’clock20/200 20/40

Finger Pressure at

7 o’clock20/30+

Observant keratoconus patients sometimes point out, “Pressing on my eye right here, my vision gets

much sharper.”

c/o Anita Nevyas Wallace, MD

Page 32: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

CK Plus CXL Technique

Page 33: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Immediately Postop CK vs Preop

Page 34: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

27 y/o F Caucasian w KCN @ 1 MoVAsc PREOP: 20/80 VAsc 1 MO PO: 20/20- Preop RFx:

-2.00 +5.50 X 170 20/25

1 MO PO RFx: pl +0.75 X 150 20/25+

Page 35: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

27 y/o F Caucasian w KCN @ 6 Mo

VAsc PREOP : 20/80 VAsc 6 MO PO : 20/25- Preop RFx: -2.00+5.50 X 170 20/25 6 MO PO RFx: pl + 1.25 X 155 20/25

Page 36: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Page 37: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Page 38: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Ongoing Data Collection

Page 39: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

There are known knowns; there are things we know that we know. There are

known unknowns; that is to say there are things that,

we now know we don't know. But there are also

unknown unknowns – there are things we do not know, we don't know. 2/12/02

Page 40: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

“Known Known”

Epi-On is safer, as effective and likely to supplant Epi-Off

Known unknown: Epi-On CXL may

“lock in” CK and become important procedure

Page 41: ®Copyright Rubinfeld 2013 CXLUSA Clinical Trial Results S. Lance Forstot, MD, FACS Corneal Consultants of Colorado Founding Partner Clinical Professor

®Copyright Rubinfeld 2013Copyright Rubinfeld 2013

Thank You